SCHEMBL13699190

SCHEMBL13699190

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CC5CCC(C4)N5C)cc3)c(F)c2)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
FGFR1 P11362 3/20 0.39
MCHR1 Q99705 3/20 0.39
PDE4D Q08499 1/20 0.39
CYP2D6 P10635 1/20 0.39
PKM P14618 2/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 2/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699277 0.90 PKM (0.45) TAS1R3TAS1R1FGFR1MCHR1PDE4D
SCHEMBL13699326 0.90 PKM (0.42) TAS1R3TAS1R1MCHR1PKMSMN1; SMN2
SCHEMBL13699206 0.87 PKM (0.45) TAS1R3TAS1R1MCHR1PDE4DCYP2D6
SCHEMBL4242226 0.87 SMN1; SMN2 (0.43) TAS1R3TAS1R1FGFR1MCHR1PDE4D
SCHEMBL13699270 0.87 PKM (0.44) TAS1R3TAS1R1PKMMAPTNPC1
SCHEMBL13699133 0.86 PKM (0.45) TAS1R3TAS1R1MCHR1PDE4DCYP2D6
SCHEMBL13699147 0.86 PKM (0.41) TAS1R3TAS1R1PKMCYP3A4
SCHEMBL13699154 0.85 PKM (0.42) TAS1R3TAS1R1MCHR1CYP2D6PKM
SCHEMBL13699114 0.85 CYP2D6 (0.45) TAS1R3TAS1R1PDE4DCYP2D6SMN1; SMN2
SCHEMBL4229209 0.84 PKM (0.43) TAS1R3TAS1R1FGFR1MCHR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R TAS1R3 1436/4885TAS1R1 1073/4885FGFR1 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.